Las Vegas -- In the dermatologist's universal quest for great results, Rhoda S. Narins, M.D., envisions a dermatological landscape where fillers work together cooperatively to treat the myriad skin problems that vary with each individual patient. These substances would ideally be temporary but long lasting, non-allergenic, and safe. It would be even better if results were immediate, achieved with less volume of the substance, and administered with minimal pain. With the variety of new fillers waiting for FDA approval, perhaps this utopia is not beyond reach.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.